In yesterday’s Wall Street session, Kiromic BioPharma Inc. (NASDAQ:KRBP) shares traded at $0.21, up 3.54% from the previous session.
KRBP stock price is now -10.59% away from the 50-day moving average and -45.25% away from the 200-day moving average. The market capitalization of the company currently stands at $3.71M.
A total of 6.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KRBP stock. A new stake in Kiromic BioPharma Inc. shares was purchased by CETERA ADVISOR NETWORKS LLC during the first quarter worth $2,000. PNC FINANCIAL SERVICES GROUP, INC. invested $1,000 in shares of KRBP during the first quarter. In total, there are 18 active investors with 1.70% ownership of the company’s stock.
On Friday morning Kiromic BioPharma Inc. (NASDAQ: KRBP) stock kicked off with the opening price of $0.2100. During the past 12 months, Kiromic BioPharma Inc. has had a low of $0.15 and a high of $1.27. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 0.20, and a quick ratio of 0.20. The fifty day moving average price for KRBP is $0.2301 and a two-hundred day moving average price translates $0.3756 for the stock.
The latest earnings results from Kiromic BioPharma Inc. (NASDAQ: KRBP) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.54, missing analysts’ expectations of -$0.38 by -0.16. This compares to -$0.40 EPS in the same period last year. The company reported revenue of $8.4 million for the quarter, compared to $6.14 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 36.7 percent.
Kiromic BioPharma Inc.(KRBP) Company Profile
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.